For instance, patients with estrogen receptor–positive breast cancer undergoing endocrine therapy may develop treatment resistance due to alterations in ESR1, ultimately reducing treatment efficacy.32,51 These factors are also important in terms of the approval process of ctDNA tests for clinical use. This evidence concerns the gene ESR1 and breast cancer.